STAT3 negatively regulates thyroid tumorigenesis

Although tyrosine-phosphorylated or activated STAT3 (pY-STAT3) is a well-described mediator of tumorigenesis, its role in thyroid cancer has not been investigated. We observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclear pY-STAT3 in tumor cells, preferentially in association with the tumor stroma. An inverse relationship between pY-STAT3 expression with tumor size and the presence of distant metastases was observed. Using human thyroid cancer-derived cell lines [harboring rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or rat sarcoma virus oncogene (RAS) alterations], we determined that IL-6/gp130/JAK signaling is responsible for STAT3 activation. STAT3 knockdown by shRNA in representative thyroid cancer cell lines that express high levels of pY-STAT3 had no effect on in vitro growth. However, xenografted short hairpin STAT3 cells generated larger tumors than control cells. Similarly, STAT3 deficiency in a murine model of BRAFV600E-induced PTC led to thyroid tumors that were more proliferative and larger than those tumors expressing STAT3wt. Genome expression analysis revealed that STAT3 knockdown resulted in the down-regulation of multiple transcripts, including the tumor suppressor insulin-like growth factor binding protein 7. Furthermore, STAT3 knockdown led to an increase in glucose consumption, lactate production, and expression of Hypoxia-inducible factor 1 (HIF1α) target genes, suggesting that STAT3 is a negative regulator of aerobic glycolysis. Our studies show that, in the context of thyroid cancer, STAT3 is paradoxically a negative regulator of tumor growth. These findings suggest that targeting STAT3 in these cancers could enhance tumor size and highlight the complexities of the role of STAT3 in tumorigenesis.

[1]  P. Soares,et al.  mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  Xueliang Gao,et al.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.

[3]  V. Poli,et al.  STAT3 can serve as a hit in the process of malignant transformation of primary cells , 2012, Cell Death and Differentiation.

[4]  Qun Chen,et al.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. , 2012, Mitochondrion.

[5]  L. Cantley,et al.  Cancer Cell Metabolism , 2012 .

[6]  Tae Yong Kim,et al.  Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas , 2012, Journal of Endocrinological Investigation.

[7]  V. Poli,et al.  From the nucleus to the mitochondria and back: The odyssey of a multitask STAT3 , 2011, Cell cycle.

[8]  Markus K. Muellner,et al.  p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma , 2011, Hepatology.

[9]  Matthew K. Knabel,et al.  Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1 , 2011, Cell.

[10]  B. Niederle,et al.  Desmoplastic stromal reaction in papillary thyroid microcarcinoma , 2011, Histopathology.

[11]  Yingbin Xiao,et al.  Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease. , 2011, Biochimie.

[12]  A. Johns,et al.  Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. , 2011, International journal of clinical and experimental pathology.

[13]  J. Bromberg,et al.  Environment, inflammation, and cancer. , 2011, Current opinion in genetics & development.

[14]  Emma Lundsmith,et al.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice , 2011, Proceedings of the National Academy of Sciences.

[15]  J. Turkson,et al.  A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction , 2010, Aging.

[16]  L. Ivashkiv,et al.  Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation , 2010, Breast Cancer Research.

[17]  M. Pierotti,et al.  IGFBP7: an oncosuppressor gene in thyroid carcinogenesis , 2010, Oncogene.

[18]  U. Dafni,et al.  Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis , 2010, Clinical Cancer Research.

[19]  Hiroyuki Yamamoto,et al.  IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.

[20]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[21]  P. Laird,et al.  Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling , 2009, PloS one.

[22]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[23]  Michael R. Green,et al.  Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines , 2009, Molecular Cancer Therapeutics.

[24]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[25]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[26]  P. Fawcett,et al.  Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.

[27]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[28]  B. Pützer,et al.  Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. , 2008, Endocrine-related cancer.

[29]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[30]  W. Ruan,et al.  Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro , 2008, Cancer biology & therapy.

[31]  J. Ricarte-Filho,et al.  Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. , 2008, Endocrine-related cancer.

[32]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[33]  T. Rosol,et al.  Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. , 2008, Cancer Research.

[34]  Tae-You Kim,et al.  STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination , 2008, Experimental & Molecular Medicine.

[35]  Robert A Gatenby,et al.  Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. , 2008, Seminars in cancer biology.

[36]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[37]  Hua Yu,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1α RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells , 2008, Molecular Cancer Research.

[38]  David E Levy,et al.  Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.

[39]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[40]  M. Chung,et al.  STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. , 2008, Experimental & molecular medicine.

[41]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[42]  V. Trovisco,et al.  Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. , 2007, Thyroid : official journal of the American Thyroid Association.

[43]  V. Trovisco,et al.  Molecular genetics of papillary thyroid carcinoma: great expectations. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[44]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[45]  Herb Chen,et al.  In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer , 2006, Anti-cancer drugs.

[46]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[47]  T. Kishimoto,et al.  Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .

[48]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[49]  L. Ivashkiv,et al.  Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.

[50]  Manuela Gariboldi,et al.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[52]  C. Tomlinson,et al.  RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. , 2005, Endocrine-related cancer.

[53]  L. Flowers,et al.  A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells , 2005, Oncogene.

[54]  J. Osinga,et al.  RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. , 2005, Cancer research.

[55]  B. Nelkin,et al.  IFI16 Is an Essential Mediator of Growth Inhibition, but Not Differentiation, Induced by the Leukemia Inhibitory Factor/JAK/STAT Pathway in Medullary Thyroid Carcinoma Cells* , 2005, Journal of Biological Chemistry.

[56]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[57]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[58]  J. Bromberg,et al.  Stat3 is required for the development of skin cancer. , 2004, The Journal of clinical investigation.

[59]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[60]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[61]  Jung Hun Song,et al.  Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. , 2003, Molecular endocrinology.

[62]  George M. Hilliard,et al.  Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-α and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-α* , 2003, The Journal of Biological Chemistry.

[63]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  C. Strock,et al.  The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway , 2003, Molecular and Cellular Biology.

[65]  D. Millhorn,et al.  Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. , 2003, The Journal of biological chemistry.

[66]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[67]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[68]  R. Hofstra,et al.  MEN2A-RET-induced cellular transformation by activation of STAT3 , 2001, Oncogene.

[69]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[70]  S. Akira,et al.  Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.

[71]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.